Physician profile
Christina E Maddox
NPI 1174749865
$4,687.31
in general payments reported to CMS, 2019-2025
47 companies · $725 in 2025
The $725 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $535 · 2021: $807 · 2022: $710 · 2023: $789 · 2024: $301 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.01 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $641.01 | 2019-2023 | |
| Astellas Pharma US INC | $408.59 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $394.20 | 2021-2025 | |
| Bausch Health US, LLC | $328.25 | 2019-2024 | Aplenzin, Wellbutrin |
| Therapeuticsmd, INC. | $240.18 | 2019-2022 | |
| Hologic Sales and Service, LLC | $230.37 | 2019-2022 | |
| Millicent US INC | $204.12 | 2023-2025 | Intrarosa, Femlyv |
| Pfizer INC. | $171.48 | 2019-2023 | |
| Exeltis, USA INC. | $146.23 | 2019-2025 | Slynd |
| Myovant Sciences INC. | $144.92 | 2021-2022 | |
| Scynexis, INC. | $142.31 | 2021-2022 | |
| Lupin INC. | $137.85 | 2019-2021 | |
| Myriad Women'S Health, INC. | $113.29 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $112.90 | 2019-2025 | |
| Evofem Biosciences, INC. | $111.14 | 2020-2025 | Solosec, Phexx, Phexxi |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $95.14 | 2019-2020 | |
| Baxter Healthcare | $81.71 | 2025 | Perclot |
| Shield Therapeutics INC | $68.44 | 2023-2025 | Accrufer |
| Amgen INC. | $67.50 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $67.47 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $62.61 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $53.85 | 2024-2025 | Zurzuvae |
| Ethicon US, LLC | $52.05 | 2025 | Vistaseal, Dermabond Prineo, Stratafix |
| Organon LLC | $51.07 | 2024-2025 | Jada System, Nexplanon |
| Vertical Pharmaceuticals, LLC | $49.44 | 2019-2020 | |
| Minerva Surgical, INC | $47.75 | 2021-2025 | |
| Coopersurgical, INC. | $43.77 | 2024 | Paragard T 380a |
| Duchesnay USA Incorporated | $41.20 | 2019 | |
| Agile Therapeutics, INC. | $40.59 | 2021 | |
| Amag Pharmaceuticals, INC. | $40.17 | 2019 | |
| Covidien LP | $30.50 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $26.06 | 2021 | |
| Allergan, INC. | $24.30 | 2020 | |
| Avion Pharmaceuticals | $23.20 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $22.59 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $19.17 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.19 | 2025 | Qelbree |
| Exact Sciences Corporation | $16.12 | 2023 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $15.92 | 2023 | Adthyza |
| Axonics, INC. | $15.44 | 2023 | Axonics |
| Eisai INC. | $14.30 | 2021 | |
| Seqirus USA INC | $13.74 | 2020 | |
| Medicem INC. | $13.26 | 2020 | |
| Convatec INC. | $12.95 | 2022 | |
| Ascend Therapeutics US, LLC | $11.70 | 2019 | |
| Zyla Life Sciences, INC. | $11.34 | 2020 | |
| Mission Pharmacal Company | $10.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Maddox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.